Anthony Nolan: Cell Therapy and Laboratory Services

Thank you for all your continued support this year. We’re proud to work with you to unlock pioneering new cell therapies. We can't wait to continue collaborating in 2025! From everyone at Anthony Nolan Cell Therapy and Laboratory Services, we wish you a wonderful festive season and a happy new year! 🎄 ❄️ 🎁

2024 has been a big year for Cell Therapy and Laboratory Services as we celebrated five decades of progress at Anthony Nolan. Get in touch to hear how our 50 years of expertise and experience can accelerate your new cell therapies for patients in the year ahead. This year we achieved a critical milestone with the announcement of the Anthony Nolan Cell Collection Centre, opening in Spring 2025. Based at Queens Medical Centre, Nottingham, the centre will provide apheresis services for transplant, research and development, getting cells to patients more quickly and ensuring all our industry partners have the cellular starting materials they need to progress their innovation projects. We can’t wait for it to open!   https://lnkd.in/gFWR_T9m  We’ve enjoyed supporting our partners across the cell and gene therapies industry. We’ve supplied cellular starting materials for multiple important research projects, including for the Cambridge Stem Cell Institute https://lnkd.in/gJ6pXKgZ the Francis Crick Institute https://lnkd.in/g9TPtGKf, and continued working with a range of partners, read more on our partnerships here:  working with Air Products UKI. We look forward to collaborating with you in 2025.   2024 has been a busy one for our Cell Therapy and Laboratory Services team; attending, exhibiting at, and sponsoring events. It was excellent to see so many of you at Advanced Therapies Congress in London and the The EBMT Annual Meeting in Glasgow. Our team will be attending more events throughout 2025 and we look forward to connecting with colleagues across the industry. We aim to develop lasting partnerships that help you accelerate advanced therapies.  This year we appointed our new Director of Business Development, David Bennett, who brings 25 years of experience from the pharmaceutical industry to our Cell Therapy and Laboratory Services team. David says, “I’m hugely excited for this next phase in Anthony Nolan’s mission to unlock the cures, treatments and transplants that will transform the future for more patients. I look forward to forging new partnerships with industry to help usher in the future of cell and gene therapies.”  David has made a real impact already and we’re looking forward to progressing his vision for 2025.  https://lnkd.in/gwRNFgBN  As we enter the new year, call us and discover how we can help you with our expansive service offering: anthonynolan.org/CTLS Pam Sami Anaily Valderrama Nikhita Bhalsod

Looking forward to starting 2025 on a high note by attending Phacilitate Advanced Therapies Conference in Dallas! (1 month to go - whoo!) We’ll have a stand with the BioIndustry Association (BIA) who are hosting the UK Pavilion (stand 849) – I feel very proud to represent Anthony Nolan: Cell Therapy and Laboratory Services across the pond to connect with therapy developers and build partnerships to facilitate the journey from bench to bedside of new therapies. From our large healthy donor registry and our HLA expertise to our cell collection and cryopreservation capabilities; we can support your R&D, pre-clinical, clinical trial and commercial needs. Get in touch, let’s have a chat and save lives together. See you there!

❗A landmark FDA decision for cellular therapy For the first time, a therapy based on mesenchymal stromal cells (MSCs) has been approved by the FDA, for the treatment of acute graft-versus-host disease (GvHD) in paediatric patients. Ryoncil, an allogeneic bone marrow-derived MSC infusion, saw positive results in clinical trials. Over half of the 54 participants experienced either a complete or partial response after 4-8 weeks of infusions. Dr Diana HERNANDEZ, Anthony Nolan’s director of immune and advanced therapies, responded to the news: “This is a positive step forward for MSC-based therapies, and we’re especially excited to see an advanced therapy approved for the treatment of GvHD – a potentially devastating disease that urgently needs new treatments. At Anthony Nolan Research Institute we investigate the potential of MSCs as immunomodulatory therapies, and our Cell Therapy & Laboratory Services provide umbilical cord tissue to groups who are working to develop their own MSC-based therapies for a range of regenerative and immunomodulatory applications.” Learn about how we can support your MSC research and development: https://bit.ly/4gFsJoy Read the full FDA statement: https://bit.ly/3P2dSIT

Don’t want to panic anyone, but it’s officially 1 month until Phacilitate Advanced Therapies Conference in Dallas! 🎉 Will you be there? It's not too late. Excited to see many of you across the pond and explore how we can work together to support the development of new therapies. We’ll have a stand with the BioIndustry Association (BIA) who are hosting the UK Pavilion (stand 849)—be sure to keep an eye out for us! Our amazing donors are ready to donate their healthy cells to advance life saving therapies, so let’s make it happen and explore how Anthony Nolan: Cell Therapy and Laboratory Services can support you. If you’ll be there, let me know—I’d love to catch up and chat about how we can collaborate. Got a little creative and threw in some animation. #ATW25 #Networking #CellAndGeneTherapy #cellandgene #CGT #AnthonyNolan #Celltherapy #Tcells #stemcells Anthony Nolan

We're heading to Phacilitate's Advanced Therapies week in Dallas 2025! Join us in attending insightful presentations, valuable discussions, and network with industry colleagues. Put in time to meet with our experts:  🗣️Pam Sami Head of Business Development- https://lnkd.in/eKWBVmmg 🗣️Anaily Valderrama Business Development Partnerships Lead-https://lnkd.in/eHXvAArY Meet us at the UK Pavillion, booth 849, and be part of the future of advanced therapies!  #ATW25 #AdvancedTherapies 

🔎🩸Potential research breakthrough in cancer immunotherapy! Researchers from Emory University have discovered a unique population of T cells that could hold the potential to revolutionise cancer immunotherapies. The activity of a subpopulation of stem-like CD4 T cells found near tumours can predict a patient’s response to immunotherapy; yet in most patients, these cells are held back from contributing to an immune response by regulatory T cells. This presents a new potential strategy to aid immunotherapy: unleash these stem-like CD4 T cells to develop into effector T cells that we know can target the nearby tumour and enhance the impact of immunotherapy. Although the research group at Emory aren’t sure exactly how stem-like CD4 T cells are inhibited from their full potential by regulatory T cells, they are embarking on further studies to discover this. It may only take a small push to disrupt the inhibition of these uniquely therapeutic cells and make the most of their existing tumour-specificity. Read the research here: https://bit.ly/3BZGnnA Work with us on your immunotherapy development projects: https://bit.ly/3AjbCt4

🏆 Allogeneic CAR-T therapy highlighted as key scientific breakthrough of 2024! The Nature Magazine 10 – Nature’s annual list of the most influential scientists of the year – has recognised Huji Xu for his work in autoimmune diseases. Xu’s team has been developing allogeneic CAR-T therapies to treat B cell-mediated autoimmune diseases. The group has seen significant success in early clinical trials, so far treating three patients without side effects and with considerable longevity. The results from these trials are extremely encouraging for anyone developing allogeneic CAR-T therapies, which have the potential to challenge autologous CAR-T in terms of price and accessibility. Our cellular starting materials have already been successfully used in an allogeneic CAR-T trial in the UK, and our breadth of donor characteristics can’t be beaten. Learn more: https://bit.ly/4g7U6Yn Read the full article: https://lnkd.in/eBz5w5-y

We've worked with stem cell charity Anthony Nolan for the last 15 years. As well as ensuring a consistent and reliable source of liquid nitrogen, we also continue to evolve their cryopreservation to keep up with growing demand. Read more about our partnership here: https://lnkd.in/eJhePbuV #AnthonyNolan #MVE #LN2

At the end of November our business development manager Nikhita Bhalsod attended ATMP Sweden's annual conference. Nikhita shared her thoughts on the event: “Sweden is paving the way forward for the ATMP field, setting a great example of how communication and collaboration between healthcare, academia and industry can boost the overall national effort. “With two days packed full of insightful talks we heard about some great advances within the hPSC space as well as the many challenges facing the field including the critical need for analytics with a focus on potency assays and the clinical manufacturing challenges of AAVs. “We also got the chance to hear about some exciting work further afield including the launch of ATMP-Norway, the benefits of using organoids in research at the reNEW Centre in Denmark and a great talk from the Netherlands on the need for scaling up ATMP specific knowledge and education.” We’re looking forward to attending many more events in 2025 so keep an eye on this page to find out where we will be! Get in touch with our expert team today: https://bit.ly/4iFtL5U